LIVE Programme
CET Time
19:35-19:50 Immunological mess in MDS: Is there a target? Shahram Kordasti (London)
19:50-20:20 Panel discussion
20:20-20:55 Controversial debate
Genetics versus epigenetics in myeloid disease?
Chair: Uwe Platzbecker (Leipzig)
Audience voting
20:20-20:25 Introduction Uwe Platzbecker (Leipzig)
20:25-20:35 Genetics Torsten Haferlach (Munich)
20:35-20:45 Epigenetics Maria (Ken) Figueroa (Miami)
Audience voting
20:45-20:55 Discussion
Friday, January 29, 2021
13:00-14:00 3 Simultaneous Meet the Expert sessions
Flow cytometry in MDS Arjan van de Loosdrecht (Amsterdam)
Technical aspects: cytogenetic and mutational analysis Torsten Haferlach (Munich)
Analysis of somatic mutations, of SNP etc. Luca Malcovati (Pavia)
SESSION IV – Diagnostic Workup and Prognostic Factors in MDS
Chairs: Ari Giagounidis (Düsseldorf) & Felicitas Thol (Hannover)
14:05-14:10 Introduction Ari Giagounidis (Düsseldorf)
Felicitas Thol (Hannover)
14:10-14:25 Morphology (including WHO 2018 classification), Ari Giagounidis (Düsseldorf)
cytogenetics and flow cytometry
14:25-14:40 Examining prognostic indicators in MDS Michael Pfeilstöcker (Vienna)
14:40-14:55 Role of comorbidities and quality of life in prognosis. Reinhard Stauder (Innsbruck)
New evaluation scales (QUALMS…)
14:55-15:25 ROUNDTABLE:
Response criteria (with recent proposed changes, IWG 2018)
Uwe Platzbecker, Pierre Fenaux, Austin Kulasekararaj, Ari Giagounidis
15:25-15:55 Controversial debate
IS NGS useful in MDS?
Chair: Ari Giagounidis (Düsseldorf)
Audience Voting
15:25-15:30 Introduction Ari Giagounidis (Düsseldorf)
15:30-15:40 No – Guillermo Sanz (Valencia)
3